Sign In
Buy ARVN
$8.03
-0.270 (-3.25%)
At Close: Jul 31, 2026
Arvinas, Inc. (ARVN) Reports Q2 Loss, Misses Revenue Estimates
09:15am, Wednesday, 06'th Aug 2025
Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to a loss of $0.49 per share a year ago.
Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update
07:00am, Wednesday, 06'th Aug 2025
– Submitted New Drug Application for vepdegestrant for the treatment of ESR1m, ER+/HER2- advanced or metastatic breast cancer –
Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025
04:05pm, Wednesday, 30'th Jul 2025
NEW HAVEN, Conn., July 30, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno
Arvinas Announces Retirement of Chief Executive Officer and Succession Plan
07:00am, Wednesday, 09'th Jul 2025
– John Houston, Ph.D., Chairperson, CEO and President at Arvinas, Announces Plans to Retire as CEO Upon Appointment of Successor – – Dr. Houston to Remain Chairperson of Arvinas Board of Directo
Wall Street Analysts Believe Arvinas (ARVN) Could Rally 89.85%: Here's is How to Trade
10:56am, Monday, 16'th Jun 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 89.9% in Arvinas (ARVN). While the effectiveness of this highly sought-after metric is questionable, the positi
Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress
07:00am, Friday, 13'th Jun 2025
– ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (also known as AITL) and transformed follicular lymphoma –
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
10:00am, Saturday, 07'th Jun 2025
NEW YORK , June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ: ARVN). Such investors are advised to conta
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Arvinas, Inc. - ARVN
12:20pm, Friday, 06'th Jun 2025
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. (“Arvinas” or the “Company”) (NASDAQ: ARVN). Such investors are advise
– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and publish
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
09:00am, Thursday, 05'th Jun 2025
NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). Such investors are advise
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting
08:28am, Thursday, 05'th Jun 2025
– Company to showcase preclinical studies of ARV-393, an investigational oral PROTAC BCL6 degrader, as a single agent in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (A
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
01:30pm, Wednesday, 04'th Jun 2025
NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). Such investors are advise
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
02:09pm, Monday, 02'nd Jun 2025
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. (“Arvinas” or the “Company”) (NASDAQ: ARVN). Such investors are advi
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
10:00am, Sunday, 01'st Jun 2025
NEW YORK , June 1, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ: ARVN). Such investors are advised to conta
Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression
08:06am, Saturday, 31'st May 2025
An experimental treatment by Pfizer and Arvinas delayed progression of breast cancer by more than three months compared to AstraZeneca's Faslodex in patients with a specific gene mutation, according t
